Pamrevlumab

Monoclonal antibody

Also known as FG-3019

DiscontinuedCTGF
Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2024), after a negative readout

FG-3019 is pamrevlumab, the anti-CTGF antibody originated by FibroGen (now Kyntra Bio). Its diabetic-kidney-disease study NCT00913393 was already terminated in 2010 because the sponsor made 'a strategic decision to shift focus to another indication', and the whole pamrevlumab program was then terminated in the second half of 2024 after negative topline data in idiopathic pulmonary fibrosis and Duchenne muscular dystrophy, per Kyntra Bio's FY2025 10-K filed 2026-03-16. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Other / comorbidity
NCT04229004 · Pancreatic Cancer Action Network
2020-01-31 – 2025-02-05 · Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
What this study did
NCT04632940 · Kyntra Bio
2021-03-03 – 2023-12-14 · Duchenne Muscular Dystrophy
What this study did
NCT04371666 · Kyntra Bio
2020-08-10 – 2023-08-17 · Duchenne Muscular Dystrophy
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT05262309 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2020-05-12 – 2022-01-01 · COVID-19 Respiratory Infection, COVID-19 Pneumonia, Covid19
What this study did
Phase 2 (6)
Other / comorbidity
NCT02606136 · Kyntra Bio
2016-01-04 – 2023-08-09 · Duchenne Muscular Dystrophy
What this study did
NCT04432298 · Kyntra Bio
2020-06-20 – 2021-03-22 · COVID-19
What this study did
NCT01890265 · Kyntra Bio
2013-07-30 – 2017-11-16 · Idiopathic Pulmonary Fibrosis
What this study did
NCT01262001 · Kyntra Bio
2011-03 – 2017-06-21 · Idiopathic Pulmonary Fibrosis
What this study did
NCT00913393 · Kyntra Bio
2009-02 – 2010-06 · Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT02210559 · Kyntra Bio
2014-07-31 – 2021-12-15 · Pancreatic Cancer (Unresectable)
What this study did
Phase 1 (5)
Other / comorbidity
NCT01181245 · Kyntra Bio
2008-12 – 2014-06 · Locally Advanced or Metastatic Pancreatic Cancer
What this study did
NCT00754143 · Kyntra Bio
2008-03 – 2009-12 · Diabetes Mellitus, Diabetic Nephropathy
What this study did
NCT00782561 · Kyntra Bio
2008-04 – 2009-06-18 · Focal Segmental Glomerulosclerosis
What this study did
NCT00102297 · Kyntra Bio
2005-01 – 2007-06 · Diabetes Mellitus
What this study did
NCT00074698 · Kyntra Bio
2003-12-08 – 2004-05 · Idiopathic Pulmonary Fibrosis
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT02851381 · Jonsson Comprehensive Cancer Center
2016-08 – 2017-08 · Pancreatic Cancer
What this study did

Competitive landscape

This drug's own stage for Chronic Hepatitis B: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pamrevlumab: this drugDiscontinuedMonoclonal antibodyCTGFnot yet gradedNo reviewed efficacy summary in this indication
Entecavir (Baraclude)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Hepatitis B Immune Globulin (HepaGam B)ApprovedProtein / enzyme therapeuticHBsAgnot yet gradedNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
Lamivudine (Epivir-HBV)
ApprovedUS marketing discontinued
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Peginterferon Alfa-2a (Pegasys)Approved—Type I interferon receptorPartial signalFeatured results are non-efficacy only in this race
Tenofovir Alafenamide (Vemlidy)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)Reliable signalFeatured results are non-efficacy only in this race
Tenofovir Disoproxil Fumarate (Viread)ApprovedSmall moleculeHIV reverse transcriptase (RT)Reliable signal
NCT00116805: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF 66.5 percentage of participants | ADV 10 mg 12.2 percentage of participants
NCT00117676: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF — Yes: 70.8 percentage of participants; No: 29.2 percentage of participants | ADV-TDF — Yes: 48.8 percentage of participants; No: 51.2 percentage of participants
Besifovir Dipivoxil (Besivo)Phase 3Small moleculeHBV polymerase (reverse transcriptase)Partial signal
NCT01937806: Primary endpoint at week 48: 80.9% with besifovir vs 84.9% with tenofovir disoproxil fumarate met the virologic response endpoint, showing non-inferiority (Ahn et al., Clin Gastroenterol Hepatol 2019).
Hepatitis B Immune Globulin (I.V.-Hepabig)Phase 3Polyclonal Antibody (human Hepatitis B Immunoglobulin)HBsAgnot yet gradedNo reviewed efficacy summary in this indication
Tenofovir Amibufenamide (Hengmu)Phase 3Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
TQA3605Phase 3—HBV core proteinnot yet gradedNo reviewed efficacy summary in this indication
TVAX-008Phase 3VaccineHepatitis B virus antigens (HBsAg + HBcAg)not yet gradedNo reviewed efficacy summary in this indication
AHB-171Phase 2RNA / oligonucleotideHBV RNAnot yet gradedNo reviewed efficacy summary in this indication
Daplusiran / TomligisiranPhase 2RNA / oligonucleotideHBV RNA (X and S transcripts)not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
HepalatidePhase 2PeptideNTCPnot yet gradedNo reviewed efficacy summary in this indication
Libevitug (HH-003)Phase 2Monoclonal antibodyHBV/HDV large envelope protein (PreS1 domain)not yet gradedNo reviewed efficacy summary in this indication
MetacavirPhase 2Small moleculeHBV reverse transcriptase (nucleoside analog)not yet gradedNo reviewed efficacy summary in this indication
REP 2139-MgPhase 2—HBsAg release (nucleic acid polymer)not yet gradedNo reviewed efficacy summary in this indication
T101Phase 2Biologic (subtype unspecified)HBV core, polymerase and envelope antigensnot yet gradedNo reviewed efficacy summary in this indication
TQA3810Phase 2—TLR8not yet gradedNo reviewed efficacy summary in this indication
CRMA-1001Phase 1/2Gene therapy / editingHBV genome (cccDNA and integrated DNA)not yet gradedNo reviewed efficacy summary in this indication
HepadvaxPhase 1/2VaccineHBsAg (PreS) immunizationnot yet gradedNo reviewed efficacy summary in this indication
Human Serum Albumin / Interferon Alpha2b Fusion ProteinPhase 1/2Biologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
LW231Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
PA1010Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
TQA3038Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
ACT201Phase 1RNA / oligonucleotideHBsAgnot yet gradedNo reviewed efficacy summary in this indication
CB06-036Phase 1—TLR8not yet gradedNo reviewed efficacy summary in this indication
DA-2803Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Entecavir (Cavir)
Phase 1(overall)
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
HECN30227Phase 1——not yet gradedNo reviewed efficacy summary in this indication
SA1211Phase 1RNA / oligonucleotideHepatitis B virus RNA (dual-target siRNA)not yet gradedNo reviewed efficacy summary in this indication
TVAX-028Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Adefovir Dipivoxil (Hepsera)DiscontinuedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Obeticholic Acid (Ocaliva)Discontinued—FXRnot yet gradedNo reviewed efficacy summary in this indication
Telbivudine (Tyzeka)Discontinued—HBV polymerase (reverse transcriptase)Partial signal
NCT00076336: Protocol composite at week 52 (HBV DNA <10,000 copies/mL, normal ALT, Child-Turcotte-Pugh score improved or stable), telbivudine vs lamivudine, ITT missing=failure: 56.2% vs 54.0%, non-inferiority not achieved (Chan et al., Aliment Pharmacol Ther 2012). missed

Upcoming events

No upcoming readouts on record for this asset.